

FOR IMMEDIATE RELEASE

June 19, 2012

**FULL SPECTRUM GENETICS ENTERS STRATEGIC COLLABORATION WITH A
LEADING GLOBAL PHARMACEUTICAL COMPANY**

SOUTH SAN FRANCISCO, Calif. – Full Spectrum Genetics, Inc., a privately-held protein analysis and engineering platform and product company, today announced a strategic collaboration with an undisclosed leading global pharmaceutical company for the purpose of generating multiple novel therapeutic protein and antibody product candidates.

Under the terms of the agreement, Full Spectrum Genetics will be responsible for engineering and analyzing variants of specified molecules using its MapEng™ platform. The pharmaceutical company will receive worldwide rights to develop and commercialize product candidates arising from the collaboration. Full Spectrum Genetics will receive an upfront payment to initiate the collaboration and is eligible for additional financial consideration. Additional terms were not disclosed.

About Full Spectrum Genetics

Founded in 2010, Full Spectrum Genetics, Inc is a privately-held protein analysis and engineering platform and product company. The Company's MapEng™ platform enables the ultra-high throughput quantification of the effect on binding of every possible single amino acid substitution within a protein binding site. The MapEng™ platform provides a comprehensive analysis of protein structure-function relationships, with multiple applications for generating better biotherapeutics and diagnostics. For more information on Full Spectrum Genetics and its MapEng™ platform, visit www.fsgene.com.

Contact:

Bob DuBridge
CEO
Full Spectrum Genetics, Inc.
650-754-7384
bob@fsgene.com